Department of Psychosocial & Community Health, University of Washington School of Nursing, 9709 3rd Avenue NE, Suite 507, Seattle, WA 98155-2053, USA.
J Gerontol B Psychol Sci Soc Sci. 2010 Nov;65(6):691-7. doi: 10.1093/geronb/gbq054. Epub 2010 Aug 6.
This article describes results of a randomized controlled trial comparing a time-limited early-stage memory loss (ESML) support group program conducted by a local Alzheimer's Association chapter to a wait-list (WL) control condition.
One hundred and forty-two dyads were randomized in blocks to ESML (n = 96) or WL (n = 46). Mean age of participants was 74.9 years, and mean Mini-Mental State Examination was 23.4. The primary outcome was participant's quality of life; secondary outcomes included mood, family communication, and perceived stress.
On the intent-to-treat (ITT) pre-post analysis, significant differences were seen in participant quality of life (p < .001), depression (p < .01), and family communication (p < .05). Within the care partner groups, there was no significant difference between ESML and WL in the ITT analysis. A post hoc exploratory examination of changes that were associated with improved quality of life in ESML participants revealed significant reductions of depressive symptoms and behavior problems (p < .05), improved family communication (p < .05), self-efficacy (p < .01), Medical Outcomes Study short form (SF-36) role-emotional (p < .05), SF-36 social functioning (p < .05), and SF-36 mental health components (p < .01) in improvers.
These results support the efficacy of ESML support groups for individuals with dementia.
本文描述了一项随机对照试验的结果，该试验比较了由当地阿尔茨海默病协会分会开展的限时早期记忆丧失（ESML）支持小组计划与候补名单（WL）对照组的结果。
142 对参与者以区块随机分配至 ESML（n=96）或 WL（n=46）组。参与者的平均年龄为 74.9 岁，平均 Mini-Mental State Examination 评分为 23.4。主要结果是参与者的生活质量；次要结果包括情绪、家庭沟通和感知压力。
在意向治疗（ITT）前后分析中，参与者的生活质量（p<.001）、抑郁（p<.01）和家庭沟通（p<.05）方面存在显著差异。在照顾者组内，ESML 和 WL 在 ITT 分析中没有显著差异。对 ESML 参与者生活质量改善相关变化的事后探索性检查显示，抑郁症状和行为问题显著减少（p<.05），家庭沟通改善（p<.05），自我效能感提高（p<.01），医疗结局研究简表（SF-36）角色情感成分（p<.05），SF-36 社会功能成分（p<.05）和 SF-36 心理健康成分（p<.01）。
这些结果支持 ESML 支持小组对痴呆症患者的疗效。
